Home/Pipeline/nAChR α6 Program

nAChR α6 Program

Chronic Pain

DiscoveryAdvanced Discovery-Stage

Key Facts

Indication

Chronic Pain

Phase

Discovery

Status

Advanced Discovery-Stage

Company

Rapport Therapeutics

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Chronic Pain Drugs

Drug	Company	Phase	Status
SCI-160	SciSparc	Preclinical	Active
Injectrode Platform for Chronic Pain	Neuronoff	Pre-clinical	Active
Novel PNS System	Nervonik	First-in-Human Completed	Active
Pain Pipeline	Centrexion Therapeutics	Clinical Stage	Active
High-Definition Spinal Cord Stimulation	Micro-Leads	Unknown	Active
Precision Medicine for Pain	MindX Sciences	Commercial	Active
Chronic Pain Program	Current Surgical	Research	Active
N-19a	Neurocarrus	Pre-clinical	Active
Nav1.7 ASO	Quiver Bioscience	Discovery	Active
Nav1.8 ASO	Quiver Bioscience	Discovery	Active
Dual Nav1.7/1.8 ASO	Quiver Bioscience	Discovery	Active
TMS for Chronic Pain	Magstim	Commercial/Clinical Development	Active